17 Dec Clinical Trials are Getting More Diverse Thanks to AI—and Humans

By Cara Brant, Applied Clinical Trials

It’s widely agreed that clinical trial participants should reflect the populations of people who will ultimately be affected by the resulting treatments. For instance, there’s no debate that since Hidradenitis Suppurativa (HS) is a condition most prominent among Black women, that trial populations for HS treatments should be proportionately populated by this demographic. But achieving this is a challenge that continues to confound the industry.

The Boston University School of Medicine recently found that efforts to boost diversity for some trials continue to fall short. While clinical trial sponsors are eager to find solutions, they still struggle to populate trials with participants that more closely reflect real-world patient populations. The federal government has acknowledged the problem, too. In the past year alone, it has taken notable steps to boost clinical trial diversity in the US through Diversity Action Plans. Read more…